Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 45 clinical trials
Talazoparib - Carboplatin for Recurrent High-grade Glioma With DDRd

In view of the strong biological rationale of employing PARP inhibition in high grade glioma, the current study purposes testing of talazoparib in a biomarker-enriched group of glioma

  • 0 views
  • 25 Aug, 2021
  • 1 location
Talazoparib for Cohesin-Mutated AML and MDS With Excess Blasts

This research study is testing if Talazoparib is an effective treatment for patients with AML and MDS that have a mutation in the cohesin complex.

azacitidine
blast cells
decitabine
cancer
white blood cell count
  • 0 views
  • 23 Jul, 2022
  • 2 locations
Talazoparib and Avelumab in Participants With Metastatic Renal Cell Carcinoma

The purpose of this study is to see whether the combination of avelumab and talazoparib can be an effective treatment for metastatic renal cell carcinoma.

platelet count
neutrophil count
oophorectomy
line of therapy
programmed cell death 1 ligand 1
  • 2 views
  • 23 Mar, 2022
  • 7 locations
ZEN003694 Combined With Talazoparib in Patients With Recurrent Ovarian Cancer

This Phase 2, open label, study with safety lead in of oral talazoparib in combination with ZEN003694 given daily in 28-day cycles will enroll patients with recurrent ovarian, fallopian tube or

platelet count
neutrophil count
cancer of the ovary
fallopian tube
BRCA1/2
  • 0 views
  • 14 May, 2022
  • 1 location
Talazoparib and Axitinib for People With Previously Treated Advanced Kidney Cancer

Researchers are doing this study to find out if the combination of the drugs axitinib and talazoparib is a safe and effective treatment for people with your previously treated advanced kidney

neutrophil count
platelet count
oophorectomy
line of therapy
programmed cell death 1 ligand 1
  • 7 views
  • 29 Jul, 2022
  • 7 locations
Talazoparib and Radiation Therapy in Treating Patients With Locally Recurrent Gynecologic Cancers

This phase I trial studies the side effects and best dose of talazoparib in combination with radiation therapy and to see how well they work in treating patients with gynecologic cancers that

neutrophil count
platelet count
ethinyl estradiol
follicle stimulating hormone
fallopian tube
  • 1 views
  • 19 Jun, 2022
  • 1 location
Enzalutamide Plus Talazoparib for the Treatment of Hormone Sensitive Prostate Cancer (ZZ-First) (ZZ-First)

This is a multicenter, open-label, randomized, two-arm, phase II clinical trial to evaluate the efficacy and safety of talazoparib (PF-06944076) in combination with enzalutamide in patients with

platelet count
adenocarcinoma of prostate
liver metastasis
bone metastases
gilbert's syndrome
  • 5 views
  • 21 Jul, 2022
  • 7 locations
A Study of ZEN003694 and Talazoparib in Patients With Triple Negative Breast Cancer (TNBC)

This is a two-part open label, non-randomized, Phase 2, study of ZEN003694 in combination with Talazoparib in patients with TNBC without germline mutations of BRCA1 or BRCA2. Part 1 is a dose

HER2
BRCA2
estrogen receptor
cancer
triple-negative breast cancer
  • 0 views
  • 27 Jul, 2022
  • 10 locations
Measuring the Effects of Talazoparib in Patients With Advanced Cancer and DNA Repair Variations

This phase II trial studies if talazoparib works in patients with cancer that has spread to other places in the body (advanced) and has mutation(s) in deoxyribonucleic acid (DNA) damage response

  • 0 views
  • 29 Jul, 2022
  • 2 locations
Selinexor & Talazoparib in Advanced Refractory Solid Tumors; Advanced/Metastatic Triple Negative Breast Cancer (START)

This is a single arm, open-label, phase I dose finding study, followed by a phase II expansion study. Phase I will be carried out in a modified 3+3 dose escalation design, with a projected enrolment of 33 patients with refractory solid tumors to determine the RP2D. In the phase II …

  • 0 views
  • 12 Sep, 2021
  • 1 location